Case Reports in Oncological Medicine最新文献

A Critical Case of Chronic Eosinophilic Leukemia: Diagnostic Criteria and Response to Cytarabine. 慢性嗜酸性粒细胞白血病1例：诊断标准和对阿糖胞苷的反应。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-09-27 eCollection Date: 2025-01-01 DOI: 10.1155/crom/8887007

Ana Karen Cruz-Acevedo, Eduardo L Pérez-Campos, María Teresa Hernández-Huerta, Miguel Cruz-Reyes, Joel López-Matías, Laura Pérez-Campos Mayoral, Víctor Cruz-Hernández

{"title":"A Critical Case of Chronic Eosinophilic Leukemia: Diagnostic Criteria and Response to Cytarabine.","authors":"Ana Karen Cruz-Acevedo, Eduardo L Pérez-Campos, María Teresa Hernández-Huerta, Miguel Cruz-Reyes, Joel López-Matías, Laura Pérez-Campos Mayoral, Víctor Cruz-Hernández","doi":"10.1155/crom/8887007","DOIUrl":"https://doi.org/10.1155/crom/8887007","url":null,"abstract":"Chronic eosinophilic leukemia (CEL) belongs to the group of chronic myeloproliferative neoplasms characterized by the persistence of an absolute eosinophil count (AEC) > 1.5 × 109/L for 1-6 months and is accompanied by organ damage. The new World Health Organization criteria for the diagnosis of CEL are the presence of the cytogenetic alteration FIP1L1::PDGFRA as an oncogene; in its absence, morphological criteria in bone marrow define the diagnosis with blasts > 5% and < 20% and in peripheral blood with > 2% of blasts and eosinophilia >1.5 × 109/L. The current study describes the case of a 60-year-old man who was admitted to the internal medicine department in critical condition with fever, cough, dyspnea, shortness of breath, and intense abdominal pain, and his spleen had the following measurements: 8-8-10 cm. The complete blood count showed hemoglobin 8.5 g/dL, platelets92 × 109/L, leukocytes105.97 × 109/L, total neutrophils31.79 × 109/L, AEC69.40 × 109/L, and lymphocytes4.23 × 109/L, and the bone marrow analysis revealed 25% eosinophils and 12% myeloblasts. Thorax and abdomen computed tomography showed interstitial infiltrate, pleural effusion, and splenomegaly. Endoscopy showed ulcerative lesions in the digestive tract. This case underscores the crucial role of both bone marrow and peripheral blood morphological criteria in diagnosing CEL. This rare disease manifests at an advanced stage with complex clinical features but responds well to cytarabine.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"8887007"},"PeriodicalIF":0.6,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12496144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isolated Leptomeningeal Carcinomatosis in Urothelial Carcinoma: A Case Report of Positive CSF Cytology With Negative Imaging. 尿路上皮癌中孤立性小脑膜癌：脑脊液细胞学阳性影像学阴性1例报告。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-09-25 eCollection Date: 2025-01-01 DOI: 10.1155/crom/8889550

Christina Lim, Eric Winquist, Mariamma Joseph, Prathana Nathan

引用次数: 0

Renal Cell Carcinoma With Myocardial Metastasis: A Case of Tumor-Induced Cardiac Tamponade After Radical Nephrectomy. 肾细胞癌合并心肌转移：根治性肾切除术后肿瘤引起的心包填塞1例。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-09-23 eCollection Date: 2025-01-01 DOI: 10.1155/crom/1493666

Hussein Haidari, Samuel C Hall, Sagar Kumar, Huseyin Kilic, Omar Alkharabsheh

引用次数: 0

Successful Treatment With Single-Fraction Stereotactic Body Radiotherapy to Lung and Reirradiation of Neck Node Metastases in a Treated Base Tongue Primary. 单段式立体定向放射治疗成功治疗基底舌原发性淋巴结转移。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-09-23 eCollection Date: 2025-01-01 DOI: 10.1155/crom/1608574

Aakriti Bhardwaj, Sindhu Tanigassalam, Shambhavi C, Shirley Lewis

{"title":"Successful Treatment With Single-Fraction Stereotactic Body Radiotherapy to Lung and Reirradiation of Neck Node Metastases in a Treated Base Tongue Primary.","authors":"Aakriti Bhardwaj, Sindhu Tanigassalam, Shambhavi C, Shirley Lewis","doi":"10.1155/crom/1608574","DOIUrl":"10.1155/crom/1608574","url":null,"abstract":"Introduction: Head and neck cancers are one of the most common cancers globally. Locoregional recurrence or distant metastasis is a common mode of recurrence and should be treated curatively, where feasible. We present a case of an elderly gentleman treated with reirradiation for nodal metastases and lung metastases ablated with single-fraction SBRT. Case Summary: An elderly 73-year-old gentleman treated with definitive radiotherapy 3 years ago for carcinoma of the base of the tongue presented with the complaint of left neck swelling for 3 weeks. A 2 × 3 cm left Level II lymph node was palpable with skin involvement. The positron emission tomography (PET) was suggestive of a left Level II cervical node measuring 4 × 4 × 3.2 cm, encasing the carotid artery and involving the skin, and a 3 × 2 cm right lower lobe lung lesion, suggestive of a metachronous lung primary or metastasis. The neck node was deemed unresectable due to more than 180-degree contact with vessels. The patient was unwilling to undergo a biopsy of the lung. Given the age, performance status and oligometastatic presentation, the patient was planned for radical intent treatment to both the neck node and the lung lesion. He was treated with reirradiation to the neck node with a dose of 66 Gy in 33 fractions over 6.5 weeks and SBRT 34 Gy in a single fraction to the lung lesion. He developed neck soft tissue necrosis, at 1.5 years after radiation, which resolved on antibiotics. The patient remains clinically well, and the PET scan performed at 1 and 2 years following radiation showed complete response with no new metastasis. Conclusion: Radical intent can be considered in oligometastatic head and neck cancers. Reirradiation is a treatment option for patients with recurrent head and neck cancers. Single-fraction SBRT is one of the recommended dose schedules for lung metastases.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"1608574"},"PeriodicalIF":0.6,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12483741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vedolizumab Dose Escalation Resolves Immune Checkpoint Inhibitor-Induced Colitis in Two Patients. Vedolizumab剂量递增解决两例患者免疫检查点抑制剂诱导的结肠炎

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-09-23 eCollection Date: 2025-01-01 DOI: 10.1155/crom/7637337

Cong Wang, Nikhil Nayee, Jacqueline M Garrick, Justin Moser

{"title":"Vedolizumab Dose Escalation Resolves Immune Checkpoint Inhibitor-Induced Colitis in Two Patients.","authors":"Cong Wang, Nikhil Nayee, Jacqueline M Garrick, Justin Moser","doi":"10.1155/crom/7637337","DOIUrl":"10.1155/crom/7637337","url":null,"abstract":"Colitis is a common side effect of all currently approved immune checkpoint inhibitors (ICIs). Vedolizumab is an α 4 β 7 monoclonal antibody approved for treating inflammatory bowel disease (IBD) and is commonly used off-label to manage checkpoint inhibitor colitis (CIC). Previous studies have attempted dose escalation of vedolizumab for clinically unresponsive IBD patients and have been able to achieve clinical remission in 49.6% of these patients without an associated increase in adverse events. However, this has yet to be reported in patients with CIC. Here, we report on two patients who developed CIC after being treated with ICIs for metastatic cancer and received a double dose of vedolizumab. Both patients' colitis was initially treated with infliximab, steroids, and standard 300-mg vedolizumab dosage with an incomplete response. When administered a double dose of 600-mg vedolizumab, colitis symptoms were resolved without further recurrence or the need for treatment in both patients. This case series outlines effective clinical experience in treating patients with CIC refractory to standard vedolizumab dosage and supports further study of vedolizumab dose escalation in this patient population.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"7637337"},"PeriodicalIF":0.6,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12483751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single Isolated Sacral Metastasis From Clear Cell Renal Cell Carcinoma: A Case Report. 透明细胞肾细胞癌单发骶骨转移一例。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-09-11 eCollection Date: 2025-01-01 DOI: 10.1155/crom/5545096

Salah Ahmed Binziad, Mohammed Abdulla Baamer, Waleed Khaled Kaleem, Moawia Mohammed Elhassan

{"title":"Single Isolated Sacral Metastasis From Clear Cell Renal Cell Carcinoma: A Case Report.","authors":"Salah Ahmed Binziad, Mohammed Abdulla Baamer, Waleed Khaled Kaleem, Moawia Mohammed Elhassan","doi":"10.1155/crom/5545096","DOIUrl":"10.1155/crom/5545096","url":null,"abstract":"This case report describes a rare occurrence of a single isolated sacral metastasis in a 59-year-old male with clear cell renal cell carcinoma (ccRCC). The patient presented with progressive lower back pain and sacral numbness following a fall. Initial imaging revealed a destructive lytic lesion in the S1-S2 region and a left renal mass. A CT-guided biopsy of the sacral lesion confirmed metastatic ccRCC. PET-CT confirmed no additional metastases. Multidisciplinary management included partial left nephrectomy for the primary renal tumor, stereotactic body radiotherapy (SBRT; 45 Gy/15 fractions) targeting the sacral metastasis, and immunotherapy with sunitinib. The patient experienced significant pain relief within 1-week post radiotherapy and demonstrated stable disease with near-resolution of the sacral lesion at 3-month follow-up. At 12 months, imaging confirmed sustained disease stability. This case highlights the importance of considering metastatic RCC in patients with isolated sacral lesions, even in the absence of disseminated disease, and underscores the efficacy of combining localized ablation, radiotherapy, and targeted systemic therapy. Early diagnosis and a tailored multidisciplinary approach are critical for optimizing outcomes in such rare presentations.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"5545096"},"PeriodicalIF":0.6,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unusual Type of Acinar Adenocarcinoma of the Prostate With Low PSA: A Histopathological Report of Two Cases of Pleomorphic Giant Cell Adenocarcinoma. 低PSA的不寻常类型前列腺腺泡腺癌：两例多形性巨细胞腺癌的组织病理学报告。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-09-09 eCollection Date: 2025-01-01 DOI: 10.1155/crom/7658657

George S Stoyanov, Andrea Kirilova, Kristina Naydenova, Hristo Popov

{"title":"Unusual Type of Acinar Adenocarcinoma of the Prostate With Low PSA: A Histopathological Report of Two Cases of Pleomorphic Giant Cell Adenocarcinoma.","authors":"George S Stoyanov, Andrea Kirilova, Kristina Naydenova, Hristo Popov","doi":"10.1155/crom/7658657","DOIUrl":"10.1155/crom/7658657","url":null,"abstract":"Introduction: Prostate adenocarcinoma is among the leading malignant neoplastic processes in overall incidence and among the leaders of cancer-related deaths. Clinically, there is a higher risk of development in males over 50, and suspicion is increased in all cases of elevated prostate-specific antigen (PSA) levels. While the most common histologies are of conventional ductal and acinar prostatic adenocarcinoma, there are some exceedingly rare histological patterns and subtypes that vary from conventional carcinomas not only in their histological makeup but also in their presentation and aggressiveness. Case Presentations: Herein, we report two cases of male patients aged 75 and 60 years who presented to our institution with the leading complaint of urinary retention and gross hematuria and concomitant hydronephrosis. In both patients, the PSA levels were within normal reference values. As such, they were scheduled for transurethral resection of the prostate, with histopathology of the resected specimens showing a pleomorphic tumor process with foci of pseudoacinar structures comprised of large atypical cells with large hyperchromic nuclei, some of which had a monstrous appearance, solid tumor cell aggregates, sheets, and single tumor cells invading the parenchyma, represented mainly by large tumor cells with macroanisokaryosis, nuclear hyperchromasia, and pronounced pleomorphism. Conclusion: Pleomorphic giant cell prostatic carcinomas rarely present with elevated PSA or specific imaging findings and are often diagnosed incidentally, further contributing to their rarity.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"7658657"},"PeriodicalIF":0.6,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12440663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defying the Prognostic Odds: A Case Report of Unexpected Complete Remission of Metastatic Ampullary Carcinoma With Palliative Chemotherapy. 无视预后的可能性：一例转移性壶腹癌在姑息性化疗下意外完全缓解的病例报告。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-09-09 eCollection Date: 2025-01-01 DOI: 10.1155/crom/7884410

Akil Olliverrie, Joel Gabin Konlack Mekontso, Jingwei Ren, Syed Karim, Imad Karam, Edwin Chiu, Christopher Chum

引用次数: 0

Nilotinib-Induced Unilateral Renal Artery Stenosis: A Complication Prompting Treatment-Free Remission in Chronic Myeloid Leukemia. 尼洛替尼诱导的单侧肾动脉狭窄：一种促进慢性髓系白血病无治疗缓解的并发症。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-09-08 eCollection Date: 2025-01-01 DOI: 10.1155/crom/9887771

Mitchell C Boshkos, Humberto R Nieves-Jiménez, Parin H Thakkar, Juan J Cintrón-García, Omar Mamlouk

{"title":"Nilotinib-Induced Unilateral Renal Artery Stenosis: A Complication Prompting Treatment-Free Remission in Chronic Myeloid Leukemia.","authors":"Mitchell C Boshkos, Humberto R Nieves-Jiménez, Parin H Thakkar, Juan J Cintrón-García, Omar Mamlouk","doi":"10.1155/crom/9887771","DOIUrl":"10.1155/crom/9887771","url":null,"abstract":"Renal artery stenosis (RAS) is a rare but significant vascular complication associated with nilotinib therapy for chronic myeloid leukemia (CML). We present the case of a woman in her mid-70s on long-term nilotinib who developed this adverse event. The patient presented with a progressive, insidious decline in renal function over several years. Diagnostic evaluation revealed severe unilateral stenosis of the left renal artery. Under nilotinib, the patient had maintained a sustained deep molecular response (DMR), making her a candidate for treatment-free remission (TFR). The development of RAS prompted the discontinuation of nilotinib, both as a therapeutic intervention for her kidney disease and to initiate a trial of TFR. Following discontinuation, the patient's renal function showed partial but significant improvement, suggesting a causal relationship. This case describes the importance of recognizing subtle presentations of TKI-induced vascular complications, particularly unilateral RAS, and illustrates how managing such adverse events intersects with modern CML therapeutic goals like TFR.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"9887771"},"PeriodicalIF":0.6,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

KIT-Negative Systemic Mastocytosis Associated With Acute Myeloid Leukemia. kit阴性全身性肥大细胞增多症与急性髓性白血病相关。

IF 0.6

Case Reports in Oncological Medicine Pub Date : 2025-09-06 eCollection Date: 2025-01-01 DOI: 10.1155/crom/3563591

Kabeer Ali, Tasnuva Rashid, Jennifer Miatech, Abhinav Karan, Zachary Chandler, Gerardo Diaz Garcia, W J R Quan

{"title":"KIT-Negative Systemic Mastocytosis Associated With Acute Myeloid Leukemia.","authors":"Kabeer Ali, Tasnuva Rashid, Jennifer Miatech, Abhinav Karan, Zachary Chandler, Gerardo Diaz Garcia, W J R Quan","doi":"10.1155/crom/3563591","DOIUrl":"10.1155/crom/3563591","url":null,"abstract":"Systemic mastocytosis (SM) is a rare blood disorder characterized by the clonal proliferation of mast cells in tissues. Mast cells release various vasoactive mediators, including histamine, leukotrienes, prostaglandins, platelet-activating factors, and cytokines such as tumor necrosis factor. Clinical manifestations can range from mild itching to severe distributive shock. In some rare cases, mastocytosis is associated with other blood disorders, such as systemic mastocytosis with associated hematologic neoplasm (SM-AHN). Almost all cases of SM exhibit a KIT point mutation. We report a rare case of KIT-negative SM associated with acute myeloid leukemia. Historically, AML has been associated with a poor prognosis, and further research is needed to understand the prognosis of SM associated with AML. In this particular case, the patient underwent induction chemotherapy with azacitidine and venetoclax, and a follow-up bone marrow biopsy showed a reduction in mastocytosis without complete hematologic recovery. The authors aim to present this case as an example of the complex nature of SM and its diverse clinical presentations.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2025 ","pages":"3563591"},"PeriodicalIF":0.6,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0